Jim Gilligan

Tryp Therapeutics, Inc. (OTCQB: TRYPF) (CSE:TRYP) has submitted an Investigational New Drug application to the U.S. Food and Drug Administration for its planned phase 2a clinical trial investigating the effects of psilocybin-assisted psychotherapy in the treatment of patients aged 21+ suffering...

Experts gathered at the Benzinga Psychedelics Capital Conference in Miami Beach on Thursday where they talked about revolutionizing psychedelic therapy as a promising new approach for treating mental health conditions and how clinical data is crucial to pulling institutional...

Numinus Updates On New Acquisition’s Integration And Provides Client Financing Options Numinus Wellness Inc. (OTCQX: NUMIF) recently acquired psychedelics company Novamind and is successfully integrating its activities: US clinics performed solidly while client appointments grew during...

Tryp Therapeutics Inc. (OTCQB: TRYPF) is a clinical-stage biotech company focused on developing psilocybin-based compounds for ill-treated diseases. Together with the University of Florida, the company is currently studying the effects of psilocybin administration on people who suffer from Binge...